1. Home
  2. SUNS vs CRDF Comparison

SUNS vs CRDF Comparison

Compare SUNS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUNS
  • CRDF
  • Stock Information
  • Founded
  • SUNS 2023
  • CRDF 1999
  • Country
  • SUNS United States
  • CRDF United States
  • Employees
  • SUNS N/A
  • CRDF N/A
  • Industry
  • SUNS Real Estate Investment Trusts
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SUNS Real Estate
  • CRDF Health Care
  • Exchange
  • SUNS Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • SUNS 130.5M
  • CRDF 152.3M
  • IPO Year
  • SUNS N/A
  • CRDF N/A
  • Fundamental
  • Price
  • SUNS $9.64
  • CRDF $2.22
  • Analyst Decision
  • SUNS Strong Buy
  • CRDF Strong Buy
  • Analyst Count
  • SUNS 3
  • CRDF 5
  • Target Price
  • SUNS $13.58
  • CRDF $11.10
  • AVG Volume (30 Days)
  • SUNS 57.4K
  • CRDF 871.9K
  • Earning Date
  • SUNS 11-13-2025
  • CRDF 10-29-2025
  • Dividend Yield
  • SUNS 12.20%
  • CRDF N/A
  • EPS Growth
  • SUNS N/A
  • CRDF N/A
  • EPS
  • SUNS 1.04
  • CRDF N/A
  • Revenue
  • SUNS $16,359,932.00
  • CRDF $545,000.00
  • Revenue This Year
  • SUNS $183.25
  • CRDF N/A
  • Revenue Next Year
  • SUNS $62.46
  • CRDF N/A
  • P/E Ratio
  • SUNS $9.23
  • CRDF N/A
  • Revenue Growth
  • SUNS 1342.10
  • CRDF N/A
  • 52 Week Low
  • SUNS $7.80
  • CRDF $1.90
  • 52 Week High
  • SUNS $15.74
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • SUNS 41.11
  • CRDF 47.68
  • Support Level
  • SUNS $9.56
  • CRDF $2.10
  • Resistance Level
  • SUNS $10.12
  • CRDF $2.38
  • Average True Range (ATR)
  • SUNS 0.36
  • CRDF 0.10
  • MACD
  • SUNS 0.03
  • CRDF 0.00
  • Stochastic Oscillator
  • SUNS 40.00
  • CRDF 29.15

About SUNS Sunrise Realty Trust Inc. Common Stock

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: